These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18034447)

  • 1. Use of evidence in economic decision models: practical issues and methodological challenges.
    Cooper NJ; Sutton AJ; Ades AE; Paisley S; Jones DR;
    Health Econ; 2007 Dec; 16(12):1277-86. PubMed ID: 18034447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems of using modelling in the economic evaluation of health care.
    Sheldon TA
    Health Econ; 1996; 5(1):1-11. PubMed ID: 8653188
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
    O'Brien BJ; Briggs AH
    Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
    Griffin SC; Weatherly HL; Richardson GA; Drummond MF
    Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care.
    Bujkiewicz S; Jones HE; Lai MC; Cooper NJ; Hawkins N; Squires H; Abrams KR; Spiegelhalter DJ; Sutton AJ
    Value Health; 2011; 14(5):768-76. PubMed ID: 21839417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The iterative use of economic evaluation as part of the process of health technology assessment.
    Sculpher M; Drummond M; Buxton M
    J Health Serv Res Policy; 1997 Jan; 2(1):26-30. PubMed ID: 10180650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of modelling in prioritising and planning clinical trials.
    Chilcott J; Brennan A; Booth A; Karnon J; Tappenden P
    Health Technol Assess; 2003; 7(23):iii, 1-125. PubMed ID: 14499052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Representing uncertainty: the role of cost-effectiveness acceptability curves.
    Fenwick E; Claxton K; Sculpher M
    Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models.
    Grimm SE; Pouwels X; Ramaekers BLT; Wijnen B; Knies S; Grutters J; Joore MA
    Pharmacoeconomics; 2020 Feb; 38(2):205-216. PubMed ID: 31709496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based decision making in healthcare in Central Eastern Europe.
    Ferrario A; Baltezarević D; Novakovic T; Parker M; Samardzic J
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):611-5. PubMed ID: 25090222
    [No Abstract]   [Full Text] [Related]  

  • 16. Are adverse effects incorporated in economic models? An initial review of current practice.
    Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
    Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of probabilistic decision models in technology assessment : the case of total hip replacement.
    Briggs A; Sculpher M; Dawson J; Fitzpatrick R; Murray D; Malchau H
    Appl Health Econ Health Policy; 2004; 3(2):79-89. PubMed ID: 15702945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.